Kyowa Hakko Kirin gears up to test IDO/PD-1 combo; AbbVie fights Humira biosimilars with 80% price cut in Europe
→ Turns out IDO is not dead yet. Kyowa Hakko Kirin has announced that it is testing its IDO inhibitor in combination with the PD-1 drug from Merck KGaA and Pfizer, avelumab. The Japanese pharma will take charge of the proof-of-concept trial in the US, which will recruit patients with solid tumors.
→ In an effort to dissipate the threat of Humira biosimilars, at least four of which launched in the EU last month, AbbVie has slashed the blockbuster rheumatoid arthritis drug’s price by 80% in European markets. That’s according to a new report from Bernstein’s Ronny Gal cited by multiple sources. Gal suggests that AbbVie’s goal here is to “defend the US market by denying the biosimilars in-market experience,” though they will still be able to make money at this price.